These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18622673)

  • 1. Peritoneal pharmacokinetics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment.
    Higuchi K; Ikawa K; Ikeda K; Ohge H; Sueda T; Houchi H; Morikawa N
    J Infect Chemother; 2008 Apr; 14(2):110-6. PubMed ID: 18622673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients.
    Ikawa K; Morikawa N; Hayato S; Ikeda K; Ohge H; Sueda T
    Int J Antimicrob Agents; 2007 Sep; 30(3):270-3. PubMed ID: 17587550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients.
    Ikawa K; Morikawa N; Matsuda S; Ikeda K; Ohge H; Takesue Y; Sueda T
    Int J Antimicrob Agents; 2007 Oct; 30(4):352-5. PubMed ID: 17644344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Penetration and exposure of cefotiam into the peritoneal fluid of abdominal surgery patients after intravenous administration.
    Ikawa K; Morikawa N; Fukuhara K; Hayato S; Ikeda K; Soga Y; Ohge H; Sueda T
    J Chemother; 2008 Jun; 20(3):319-23. PubMed ID: 18606586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of breakpoints of cephems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in the peritoneal fluid of patients.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T
    J Infect Chemother; 2008 Apr; 14(2):141-6. PubMed ID: 18622678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peritoneal pharmacokinetics and pharmacodynamic target attainment of meropenem in patients undergoing abdominal surgery.
    Soga Y; Ohge H; Ikawa K; Morikawa N; Ikeda K; Sueda T
    J Chemother; 2010 Apr; 22(2):98-102. PubMed ID: 20435568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T
    Diagn Microbiol Infect Dis; 2008 Nov; 62(3):292-7. PubMed ID: 18703305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T
    Int J Antimicrob Agents; 2008 Oct; 32(4):339-43. PubMed ID: 18602798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment.
    Murao N; Ohge H; Ikawa K; Watadani Y; Uegami S; Shigemoto N; Shimada N; Yano R; Kajihara T; Uemura K; Murakami Y; Morikawa N; Sueda T
    Int J Antimicrob Agents; 2017 Sep; 50(3):393-398. PubMed ID: 28694230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetration into and exposure of cefozopran in pelvic retroperitoneal space exudate.
    Ikawa K; Mikamo H; Morikawa N; Ikeda K; Tamaya T
    J Infect Chemother; 2008 Apr; 14(2):170-1. PubMed ID: 18622684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients.
    Ikawa K; Morikawa N; Sakamoto K; Ikeda K; Ohge H; Takesue Y; Sueda T
    Chemotherapy; 2008; 54(2):131-9. PubMed ID: 18303262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.
    Lee SY; Kuti JL; Nicolau DP
    J Infect; 2007 May; 54(5):463-8. PubMed ID: 17067681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.
    Crandon JL; Bulik CC; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1111-6. PubMed ID: 20038614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment.
    Nakamura K; Ikawa K; Nishikawa G; Kobayashi I; Tobiume M; Sugie M; Muramatsu H; Morinaga S; Kajikawa K; Watanabe M; Kanao K; Onita T; Morikawa N
    J Infect Chemother; 2020 Feb; 26(2):236-241. PubMed ID: 31822449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.